Emerging Research

New Clinical Trial for Myelofibrosis Patients with JAK2 Mutation

Promising results are being found in a new clinical trial for JAK2 mutation positive myelofibrosis patients.

Andrew Schorr, Srinivas K. Tantravahi, MBBS, MRCP

Hereditary Trends in MPNs

Does my risk for having an MPN increase if a close relative is diagnosed?

Angela Fleischman, MD, PhD, Esther Schorr

Latest News

Ropeginterferon Offers New Option for Treatment of MPNs

Ruth Fein, Jeanne Palmer, MD

Myeloproliferative Neoplasms in Children and Young Adults

Esther Schorr, Nicole Kucine, MD, Portia Pliam

Navitoclax in Combination for Myelofibrosis Patients

Srdan Verstovsek, MD, PhD, Andrew Schorr

The Road to Curing MPNs

Ruth Fein, Ross L. Levine, MD

ASH 2020 MPN Daily Wrap-Up: New Research and Early Detection

Andrew Schorr, Esther Schorr, Naveen Pemmaraju, MD, Michael Mauro, MD

MPN Ask Me Anything: New Medications, Clinical Trials and More

Esther Schorr, Ruben Mesa, MD

New Phase 3 Clinical Trial for Myelofibrosis Patients

Andrew Schorr, John Mascarenhas, MD

The Leading Edge of Myeloproliferative Neoplasms Treatment

Ruth Fein, Srdan Verstovsek, MD, PhD, Andrew Schorr

MPN Experts Discuss Clinical Trials and Transplants

Jeanne Palmer, MD, Naveen Pemmaraju, MD, Phil Arner, Andrew Schorr

New Drugs Advance MPN Treatment Options

Jeanne Palmer, MD, Naveen Pemmaraju, MD, Andrew Schorr

MDM2 Study: How Can Polycythemia Vera Patients Get Involved?

Jason Gotlib, MD, MS, Andrew Schorr

Emerging Role of MDM2 in Myelofibrosis Care

Srdan Verstovsek, MD, PhD, Andrew Schorr